▟ Vinebot intrinsic value, daily

← back

A Agilent Technologies

pharma · valued with opus medium conviction · deep-dived 2026-11-05

HOLD
Intrinsic value$95.70
Price (at call)$177.17
Margin of safety -46.0%
vs market (rating basis) -7.7%

A quality recurring-revenue tools franchise in recovery, but at about 2x my value the price assumes perfection.

The story

Agilent is a mature life-science and diagnostics tools franchise. About two-thirds of revenue is recurring (consumables, service contracts, software), and that base sits on a large installed base of LC/MS and genomics instruments. After a 2023-24 destocking and China-driven trough, revenue is recovering: TTM is $7.37B, up about 6% on FY24. The moat is customer lock-in through validated workflows and service attach. Growth is still mid-single-digit, held back by pharma and academic capex cycles and tariff/China exposure.

The facts confirm the recovery story, so I kept every driver except a small move in year-1 growth from 6% to 6.5% (under 20% relative), reflecting TTM revenue up about 6% with order momentum improving. The margin target stays at 26%: the current 23.9% is below the 2019-21 run-rate, and the Ignite cost program supports a return to the mid-20s, not the peak. Sales-to-capital stays at an incremental 1.5 because the reported 0.73 is inflated by acquisition goodwill and overstates what organic growth costs to fund.

Value drivers

Revenue growth (Y1)6.5%
Terminal growth3.5%
Forecast horizon10y
Target operating margin26.0%
Years to target margin5
Sales-to-capital1.50
Beta1.00
Failure probability1.0%
Cost of capital (WACC)9.2%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF12.26B
PV of terminal value16.56B
Equity value26.98B
÷ shares → per share$95.70

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 7.85B 6.5% 24.3% 1.74B 319.45M 1.42B 1.30B
2 8.34B 6.2% 24.8% 1.87B 322.77M 1.55B 1.30B
3 8.82B 5.8% 25.2% 2.02B 324.15M 1.69B 1.30B
4 9.31B 5.5% 25.6% 2.16B 323.46M 1.84B 1.29B
5 9.79B 5.2% 26.0% 2.31B 320.57M 1.99B 1.28B
6 10.26B 4.8% 26.0% 2.42B 315.38M 2.11B 1.24B
7 10.72B 4.5% 26.0% 2.53B 307.82M 2.22B 1.20B
8 11.17B 4.2% 26.0% 2.64B 297.84M 2.34B 1.16B
9 11.60B 3.8% 26.0% 2.74B 285.43M 2.45B 1.11B
10 12.00B 3.5% 26.0% 2.83B 270.60M 2.56B 1.07B

Key risks

  • Pharma and biotech capex stays soft, or the NIH and academic funding cuts deepen
  • China demand weakness and tariff-driven cost pressure compress margins
  • Acquisitive reinvestment (e.g., BioVectra-style deals) earns returns below the cost of capital

Catalysts

  • A sustained instrument replacement cycle in LC/LC-MS that lifts growth back above 7%
  • Delivery of the Ignite margin program toward a 26%+ operating margin

History

DatePriceIntrinsicMoSRating
2026-11-05$177.17 $95.70 -46.0% HOLD
2026-10-02$166.68 $88.94 -46.6% HOLD
2026-08-31$153.84 $67.45 -56.2% HOLD
2026-07-29$140.54 $76.10 -45.9% HOLD
2026-06-25$131.63 $79.80 -39.4% BUY
2026-06-23$126.84 $96.41 -24.0% BUY